Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. G. Casali; S. Bielack; N. Abecassis; H. T. Aro; S. Bauer; R. Biagini; S. Bonvalot; I. Boukovinas; J. V.M.G. Bovee; B. Brennan; T. Brodowicz; J. M. Broto; L. Brugières; A. Buonadonna; E. De Álava; A. P. Dei Tos; X. G. Del Muro; P. Dileo; C. Dhooge; M. Eriksson; F. Fagioli; A. Fedenko; V. Ferraresi; A. Ferrari; S. Ferrari; A. M. Frezza; N. Gaspar; S. Gasperoni; H. Gelderblom; T. Gil; G. Grignani; A. Gronchi; R. L. Haas; B. Hassan; S. Hecker-Nolting; P. Hohenberger; R. Issels; H. Joensuu; R. L. Jones; I. Judson; P. Jutte; S. Kaal; L. Kager; B. Kasper; K. Kopeckova; D. A. Krákorová; R. Ladenstein; A. Le Cesne; I. Lugowska; O. Merimsky; M. Montemurro; B. Morland; M. A. Pantaleo; R. Piana; P. Picci; S. Piperno-Neumann; A. L. Pousa; P. Reichardt; M. H. Robinson; P. Rutkowski; A. A. Safwat; P. Schöffski; S. Sleijfer; S. Stacchiotti; S. J. Strauss; K. Sundby Hall; M. Unk; F. Van Coevorden; W. T.A. Van Der Graaf; J. Whelan; E. Wardelmann; O. Zaikova; J. Y. Blay

doi:10.1093/annonc/mdy310

Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. G. Casali, S. Bielack, N. Abecassis, H. T. Aro, S. Bauer, R. Biagini, S. Bonvalot, I. Boukovinas, J. V.M.G. Bovee, B. Brennan, T. Brodowicz, J. M. Broto, L. Brugières, A. Buonadonna, E. De Álava, A. P. Dei Tos, X. G. Del Muro, P. Dileo, C. Dhooge, M. ErikssonF. Fagioli, A. Fedenko, V. Ferraresi, A. Ferrari, S. Ferrari, A. M. Frezza, N. Gaspar, S. Gasperoni, H. Gelderblom, T. Gil, G. Grignani, A. Gronchi, R. L. Haas, B. Hassan, S. Hecker-Nolting, P. Hohenberger, R. Issels, H. Joensuu, R. L. Jones, I. Judson, P. Jutte, S. Kaal, L. Kager, B. Kasper, K. Kopeckova, D. A. Krákorová, R. Ladenstein, A. Le Cesne, I. Lugowska, O. Merimsky, M. Montemurro, B. Morland, M. A. Pantaleo, R. Piana, P. Picci, S. Piperno-Neumann, A. L. Pousa, P. Reichardt, M. H. Robinson, P. Rutkowski, A. A. Safwat, P. Schöffski, S. Sleijfer, S. Stacchiotti, S. J. Strauss, K. Sundby Hall, M. Unk, F. Van Coevorden, W. T.A. Van Der Graaf, J. Whelan, E. Wardelmann, O. Zaikova, J. Y. Blay

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

412 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	iv79-iv95
journal	Annals of Oncology
Volume	29
Les DOIs	https://doi.org/10.1093/annonc/mdy310
état	Publié - 1 oct. 2018

Accès au document

10.1093/annonc/mdy310

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Casali, P. G., Bielack, S., Abecassis, N., Aro, H. T., Bauer, S., Biagini, R., Bonvalot, S., Boukovinas, I., Bovee, J. V. M. G., Brennan, B., Brodowicz, T., Broto, J. M., Brugières, L., Buonadonna, A., De Álava, E., Dei Tos, A. P., Del Muro, X. G., Dileo, P., Dhooge, C., ... Blay, J. Y. (2018). Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29, iv79-iv95. https://doi.org/10.1093/annonc/mdy310

@article{3d4adb571d514e09bb1e4659dcd15105,

title = "Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up",

author = "Casali, {P. G.} and S. Bielack and N. Abecassis and Aro, {H. T.} and S. Bauer and R. Biagini and S. Bonvalot and I. Boukovinas and Bovee, {J. V.M.G.} and B. Brennan and T. Brodowicz and Broto, {J. M.} and L. Brugi{\`e}res and A. Buonadonna and {De {\'A}lava}, E. and {Dei Tos}, {A. P.} and {Del Muro}, {X. G.} and P. Dileo and C. Dhooge and M. Eriksson and F. Fagioli and A. Fedenko and V. Ferraresi and A. Ferrari and S. Ferrari and Frezza, {A. M.} and N. Gaspar and S. Gasperoni and H. Gelderblom and T. Gil and G. Grignani and A. Gronchi and Haas, {R. L.} and B. Hassan and S. Hecker-Nolting and P. Hohenberger and R. Issels and H. Joensuu and Jones, {R. L.} and I. Judson and P. Jutte and S. Kaal and L. Kager and B. Kasper and K. Kopeckova and Kr{\'a}korov{\'a}, {D. A.} and R. Ladenstein and {Le Cesne}, A. and I. Lugowska and O. Merimsky and M. Montemurro and B. Morland and Pantaleo, {M. A.} and R. Piana and P. Picci and S. Piperno-Neumann and Pousa, {A. L.} and P. Reichardt and Robinson, {M. H.} and P. Rutkowski and Safwat, {A. A.} and P. Sch{\"o}ffski and S. Sleijfer and S. Stacchiotti and Strauss, {S. J.} and {Sundby Hall}, K. and M. Unk and {Van Coevorden}, F. and {Van Der Graaf}, {W. T.A.} and J. Whelan and E. Wardelmann and O. Zaikova and Blay, {J. Y.}",

note = "Funding Information: PGC has reported advisory roles for Deciphera Pharmaceuticals, Eisai, Eli Lilly, Nektar Therapeutics, speaker{\textquoteright}s honoraria from Eisai, Eli Lilly, Pfizer, PharmaMar, and conducted studies sponsored by Amgen Domp{\'e}, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SBi has reported advisory/consultant roles for Lilly, Bayer, Pfizer, Novartis, Isolfol and Clinigen and conducted studies sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBa has reported research support from Novartis, Incyte, Blueprint Medicines, has received honoraria or consultation fees from Novartis, Lilly, Pfizer, PharmaMar and Bayer; SBi has reported advisory/consultant roles for Lilly, Bayer, Pfizer, Novartis, Isolfol and Clinigen and conducted studies sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBo has reported honoraria and travel grants from Nanobiotix and Lilly and received travel grants from PharmaMar; IB has reported research funds from MSD, Bristol-Myers Squibb, Novartis, Roche, Regeneron, Amgen, Astra-Zeneca, Boehringer Ingelheim and Genesis and advisory boards, honorarium and travel expenses from MSD, Bristol-Myers Squibb, Novartis, Roche, Amgen, Astra-Zeneca, Boehringer Ingelheim, LEO Pharma, Galenica, Genesis and Sanofi; JVMGB has received a research grant from Servier and honoraria from Nanobiotix for reviewing cases for their trial; TB has reported honoraria from Roche and PharmaMar and advisory board and honoraria from Amgen, Bayer, Novartis, Eisai and Eli Lilly; JMB has reported consulting advisory role for PharmaMar, Lilly, Bayer, Novartis and being a member of the speaker{\textquoteright}s bureau for PharmaMar and received travel grants from PharmaMar and Lilly; EDA has received honoraria from PharmaMar, Roche, Lilly and Pfizer and travel grants from Roche; APDT is a member of the speakers{\textquoteright} bureau for Lilly, Pfizer and Merck Sharp & Dohme; XGDM has reported advisory role for Lilly, PharmaMar and Novartis; PD has reported conducted research sponsored by Eli Lilly; ME has participated in advisory boards for Bayer, Sobi, Lilly, Eisai and Novartis; AMF has conducted studies sponsored by Amgen Domp{\'e}, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SG has received research grants and honoraria from Novartis, Pfizer and Bayer; HG has received research grants from Novartis, Daiichi Sankyo Pharma and Pfizer; AG has reported compensation for advisory boards from Novartis, Pfizer, Bayer, Lilly, PharmaMar and Nanobiotix, honoraria from Novartis, Lilly, PharmaMar and Nanobiotix, and research funds from PharmaMar and travel grants from PharmaMar and Nanobiotix; BH has received research grants from EuroSarc and has conducted research with EIT Health in collaboration with GE Healthcare and Philips and has received reagents from Takeda and Astellas to conduct clinical trials without direct funding; PH has reported conducting research sponsored by Novartis, Blueprint Medicines, Nanobiotix and Lilly and has received honoraria and travel grants from PharmaMar, Eisai and Lilly; HJ has reported co-appointment with Orion Pharma and holds stock in Sartar Therapeutics, Faron Pharmaceuticals and Orion Pharma; RLJ is a consultant for Adaptimmune, Blueprint Medicines, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck and PharmaMar; IJ has received honoraria from Lilly for lectures; PJ has reported being a consultant for Stryker for the design of a new tumour prosthesis; BK has reported honoraria from Bayer, Lilly, Novartis and PharmaMar, advisory role for Bayer and Lilly and travel grants from PharmaMar; KK has received travel grants from Novartis and Pfizer; ALC has received honoraria from Pfizer, Novartis, Lilly, Amgen, Bayer and PharmaMar; IL has received honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Novartis and Pfizer for scientific presentations or research; MAP has served on advisory boards for Bayer and Pfizer, and has received research grants from Novartis; PRe has served on advisory boards for Novartis, Pfizer, PharmaMar, Ariad, Merck, Deciphera, Roche, Clinigen and Lilly and has received honoraria from Novartis, Pfizer, Bayer, PharmaMar and Lilly; PRu has received honoraria for lectures from Novartis, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche and has served as a member of advisory board for Novartis, Amgen, Merck Sharp & Dohme, Bristol-Myers Squibb, Blueprint Medicines; PS has received honoraria from Daiichi Sankyo Pharma, Eisai, Eli Lilly, Medspace, Novartis, Swedish Orphan Biovitrium, has reported consulting or advising roles for Sixth Element Capital, Adaptaimmune, Amcure, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boeringer Ingelheim, Cristal Therapeutics, Daiichi Sankyo Pharma, Eisai, Eli Lilly, Epizyme, Genzyme, Ipsen, Loxo Oncology, Medspace, Nektar, Novartis, Philogen, Piqur Therapeutics, Plexxikon, is a member of speaker{\textquoteright}s bureau of Bayer, Eisai, Eli Lilly, GlaxoSmithKline, Novartis, PharmaMar, Swedish Orphan Biovitrium, has received research grants from Bayer, Blueprint Medicines, CoBioRes, Exelixis, Bristol-Myers Squibb, Novartis, Plexxikon, and has received travel grants from Sixth Element Capital, Adaptaimmune, Amcure, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Cristal Therapeutics, Daichii Sankyo Pharma, Eisai, Eli Lilly, Epizyme, Genzyme, GlaxoSmithKline, Ipsen, Loxo Oncology, Medpace, Nektar, Novartis, PharmaMar, Philogen, Piqur Therapeutics, Plexxikon, Swedish Orphan Biovitrium; SSt has received honoraria from Eli Lilly and PharmaMar, research grants from Amgen Domp{\'e}, Advenchen, Bayer, Eli Lilly, Daiichi Sankyo Pharma, Epizyme Inc., Novartis, Pfizer and PharmaMar; travel grants from PharmaMar and has reported advisory/consultant roles for Bayer, Eli Lilly, ImmuneDesign, Maxivax and PharmaMar; WVdG has received research grants from Novartis; EW has reported travel/research grants and/or honoraria from Novartis Oncology, Milestone, Menarini, PharmaMar, Roche, Nanobiotix and Bayer; JYB has declared research grants and honoraria from Novartis, GlaxoSmithKline, Pfizer and Bayer; NA, RB, BB, LB, AB, CD, FF, AFed, VF, AFer, NG, TG, RLH, SHN, RI, SK, LK, DAK, RL, OM, MM, BM, RP, PP, SP-N, ALP, MHR, AAS, SSl, SStr, KSH, MU, JW and FVC have declared no conflicts of interest. SF, AH and OZ have not reported any potential conflicts of interest.",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy310",

language = "English",

volume = "29",

pages = "iv79--iv95",

journal = "Annals of Oncology",

issn = "0923-7534",

}

Casali, PG, Bielack, S, Abecassis, N, Aro, HT, Bauer, S, Biagini, R, Bonvalot, S, Boukovinas, I, Bovee, JVMG, Brennan, B, Brodowicz, T, Broto, JM, Brugières, L, Buonadonna, A, De Álava, E, Dei Tos, AP, Del Muro, XG, Dileo, P, Dhooge, C, Eriksson, M, Fagioli, F, Fedenko, A, Ferraresi, V, Ferrari, A, Ferrari, S, Frezza, AM, Gaspar, N, Gasperoni, S, Gelderblom, H, Gil, T, Grignani, G, Gronchi, A, Haas, RL, Hassan, B, Hecker-Nolting, S, Hohenberger, P, Issels, R, Joensuu, H, Jones, RL, Judson, I, Jutte, P, Kaal, S, Kager, L, Kasper, B, Kopeckova, K, Krákorová, DA, Ladenstein, R, Le Cesne, A, Lugowska, I, Merimsky, O, Montemurro, M, Morland, B, Pantaleo, MA, Piana, R, Picci, P, Piperno-Neumann, S, Pousa, AL, Reichardt, P, Robinson, MH, Rutkowski, P, Safwat, AA, Schöffski, P, Sleijfer, S, Stacchiotti, S, Strauss, SJ, Sundby Hall, K, Unk, M, Van Coevorden, F, Van Der Graaf, WTA, Whelan, J, Wardelmann, E, Zaikova, O & Blay, JY 2018, 'Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up', Annals of Oncology, VOL. 29, p. iv79-iv95. https://doi.org/10.1093/annonc/mdy310

TY - JOUR

T1 - Bone sarcomas

T2 - ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

AU - Casali, P. G.

AU - Bielack, S.

AU - Abecassis, N.

AU - Aro, H. T.

AU - Bauer, S.

AU - Biagini, R.

AU - Bonvalot, S.

AU - Boukovinas, I.

AU - Bovee, J. V.M.G.

AU - Brennan, B.

AU - Brodowicz, T.

AU - Broto, J. M.

AU - Brugières, L.

AU - Buonadonna, A.

AU - De Álava, E.

AU - Dei Tos, A. P.

AU - Del Muro, X. G.

AU - Dileo, P.

AU - Dhooge, C.

AU - Eriksson, M.

AU - Fagioli, F.

AU - Fedenko, A.

AU - Ferraresi, V.

AU - Ferrari, A.

AU - Ferrari, S.

AU - Frezza, A. M.

AU - Gaspar, N.

AU - Gasperoni, S.

AU - Gelderblom, H.

AU - Gil, T.

AU - Grignani, G.

AU - Gronchi, A.

AU - Haas, R. L.

AU - Hassan, B.

AU - Hecker-Nolting, S.

AU - Hohenberger, P.

AU - Issels, R.

AU - Joensuu, H.

AU - Jones, R. L.

AU - Judson, I.

AU - Jutte, P.

AU - Kaal, S.

AU - Kager, L.

AU - Kasper, B.

AU - Kopeckova, K.

AU - Krákorová, D. A.

AU - Ladenstein, R.

AU - Le Cesne, A.

AU - Lugowska, I.

AU - Merimsky, O.

AU - Montemurro, M.

AU - Morland, B.

AU - Pantaleo, M. A.

AU - Piana, R.

AU - Picci, P.

AU - Piperno-Neumann, S.

AU - Pousa, A. L.

AU - Reichardt, P.

AU - Robinson, M. H.

AU - Rutkowski, P.

AU - Safwat, A. A.

AU - Schöffski, P.

AU - Sleijfer, S.

AU - Stacchiotti, S.

AU - Strauss, S. J.

AU - Sundby Hall, K.

AU - Unk, M.

AU - Van Coevorden, F.

AU - Van Der Graaf, W. T.A.

AU - Whelan, J.

AU - Wardelmann, E.

AU - Zaikova, O.

AU - Blay, J. Y.

N1 - Funding Information: PGC has reported advisory roles for Deciphera Pharmaceuticals, Eisai, Eli Lilly, Nektar Therapeutics, speaker’s honoraria from Eisai, Eli Lilly, Pfizer, PharmaMar, and conducted studies sponsored by Amgen Dompé, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SBi has reported advisory/consultant roles for Lilly, Bayer, Pfizer, Novartis, Isolfol and Clinigen and conducted studies sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBa has reported research support from Novartis, Incyte, Blueprint Medicines, has received honoraria or consultation fees from Novartis, Lilly, Pfizer, PharmaMar and Bayer; SBi has reported advisory/consultant roles for Lilly, Bayer, Pfizer, Novartis, Isolfol and Clinigen and conducted studies sponsored by Janssen-Cilag, Eisai and Loxo Oncology; SBo has reported honoraria and travel grants from Nanobiotix and Lilly and received travel grants from PharmaMar; IB has reported research funds from MSD, Bristol-Myers Squibb, Novartis, Roche, Regeneron, Amgen, Astra-Zeneca, Boehringer Ingelheim and Genesis and advisory boards, honorarium and travel expenses from MSD, Bristol-Myers Squibb, Novartis, Roche, Amgen, Astra-Zeneca, Boehringer Ingelheim, LEO Pharma, Galenica, Genesis and Sanofi; JVMGB has received a research grant from Servier and honoraria from Nanobiotix for reviewing cases for their trial; TB has reported honoraria from Roche and PharmaMar and advisory board and honoraria from Amgen, Bayer, Novartis, Eisai and Eli Lilly; JMB has reported consulting advisory role for PharmaMar, Lilly, Bayer, Novartis and being a member of the speaker’s bureau for PharmaMar and received travel grants from PharmaMar and Lilly; EDA has received honoraria from PharmaMar, Roche, Lilly and Pfizer and travel grants from Roche; APDT is a member of the speakers’ bureau for Lilly, Pfizer and Merck Sharp & Dohme; XGDM has reported advisory role for Lilly, PharmaMar and Novartis; PD has reported conducted research sponsored by Eli Lilly; ME has participated in advisory boards for Bayer, Sobi, Lilly, Eisai and Novartis; AMF has conducted studies sponsored by Amgen Dompé, AROG Bayer, Blueprint Medicines, Eli Lilly, Daiichi Sankyo Pharma, Epizyme, GlaxoSmithKline, Novartis, Pfizer, PharmaMar; SG has received research grants and honoraria from Novartis, Pfizer and Bayer; HG has received research grants from Novartis, Daiichi Sankyo Pharma and Pfizer; AG has reported compensation for advisory boards from Novartis, Pfizer, Bayer, Lilly, PharmaMar and Nanobiotix, honoraria from Novartis, Lilly, PharmaMar and Nanobiotix, and research funds from PharmaMar and travel grants from PharmaMar and Nanobiotix; BH has received research grants from EuroSarc and has conducted research with EIT Health in collaboration with GE Healthcare and Philips and has received reagents from Takeda and Astellas to conduct clinical trials without direct funding; PH has reported conducting research sponsored by Novartis, Blueprint Medicines, Nanobiotix and Lilly and has received honoraria and travel grants from PharmaMar, Eisai and Lilly; HJ has reported co-appointment with Orion Pharma and holds stock in Sartar Therapeutics, Faron Pharmaceuticals and Orion Pharma; RLJ is a consultant for Adaptimmune, Blueprint Medicines, Clinigen, Eisai, Epizyme, Daichii, Deciphera, Immunedesign, Lilly, Merck and PharmaMar; IJ has received honoraria from Lilly for lectures; PJ has reported being a consultant for Stryker for the design of a new tumour prosthesis; BK has reported honoraria from Bayer, Lilly, Novartis and PharmaMar, advisory role for Bayer and Lilly and travel grants from PharmaMar; KK has received travel grants from Novartis and Pfizer; ALC has received honoraria from Pfizer, Novartis, Lilly, Amgen, Bayer and PharmaMar; IL has received honoraria from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche, Novartis and Pfizer for scientific presentations or research; MAP has served on advisory boards for Bayer and Pfizer, and has received research grants from Novartis; PRe has served on advisory boards for Novartis, Pfizer, PharmaMar, Ariad, Merck, Deciphera, Roche, Clinigen and Lilly and has received honoraria from Novartis, Pfizer, Bayer, PharmaMar and Lilly; PRu has received honoraria for lectures from Novartis, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Roche and has served as a member of advisory board for Novartis, Amgen, Merck Sharp & Dohme, Bristol-Myers Squibb, Blueprint Medicines; PS has received honoraria from Daiichi Sankyo Pharma, Eisai, Eli Lilly, Medspace, Novartis, Swedish Orphan Biovitrium, has reported consulting or advising roles for Sixth Element Capital, Adaptaimmune, Amcure, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boeringer Ingelheim, Cristal Therapeutics, Daiichi Sankyo Pharma, Eisai, Eli Lilly, Epizyme, Genzyme, Ipsen, Loxo Oncology, Medspace, Nektar, Novartis, Philogen, Piqur Therapeutics, Plexxikon, is a member of speaker’s bureau of Bayer, Eisai, Eli Lilly, GlaxoSmithKline, Novartis, PharmaMar, Swedish Orphan Biovitrium, has received research grants from Bayer, Blueprint Medicines, CoBioRes, Exelixis, Bristol-Myers Squibb, Novartis, Plexxikon, and has received travel grants from Sixth Element Capital, Adaptaimmune, Amcure, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Boehringer Ingelheim, Cristal Therapeutics, Daichii Sankyo Pharma, Eisai, Eli Lilly, Epizyme, Genzyme, GlaxoSmithKline, Ipsen, Loxo Oncology, Medpace, Nektar, Novartis, PharmaMar, Philogen, Piqur Therapeutics, Plexxikon, Swedish Orphan Biovitrium; SSt has received honoraria from Eli Lilly and PharmaMar, research grants from Amgen Dompé, Advenchen, Bayer, Eli Lilly, Daiichi Sankyo Pharma, Epizyme Inc., Novartis, Pfizer and PharmaMar; travel grants from PharmaMar and has reported advisory/consultant roles for Bayer, Eli Lilly, ImmuneDesign, Maxivax and PharmaMar; WVdG has received research grants from Novartis; EW has reported travel/research grants and/or honoraria from Novartis Oncology, Milestone, Menarini, PharmaMar, Roche, Nanobiotix and Bayer; JYB has declared research grants and honoraria from Novartis, GlaxoSmithKline, Pfizer and Bayer; NA, RB, BB, LB, AB, CD, FF, AFed, VF, AFer, NG, TG, RLH, SHN, RI, SK, LK, DAK, RL, OM, MM, BM, RP, PP, SP-N, ALP, MHR, AAS, SSl, SStr, KSH, MU, JW and FVC have declared no conflicts of interest. SF, AH and OZ have not reported any potential conflicts of interest.

PY - 2018/10/1

Y1 - 2018/10/1

UR - http://www.scopus.com/inward/record.url?scp=85054400972&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdy310

DO - 10.1093/annonc/mdy310

M3 - Article

C2 - 30285218

AN - SCOPUS:85054400972

SN - 0923-7534

VL - 29

SP - iv79-iv95

JO - Annals of Oncology

JF - Annals of Oncology

ER -